Irritable Bowel Syndrome (IBS) Treatment Market Outlook Highlights Strategic Opportunities Across The Industry

The irritable bowel syndrome (IBS) treatment market is set for substantial expansion over the coming years as advancements in medicine and technology reshape patient care. Innovations in treatment approaches, combined with growing healthcare investments and digital health integration, are driving momentum. Here's an overview of the market's expected growth, key players, emerging trends, and segmentation.

Projected Market Growth and Size of the IBS Treatment Market
The irritable bowel syndrome treatment market is anticipated to reach a value of $10.65 billion by 2030, growing at a compound annual growth rate (CAGR) of 7.5%. This robust growth is fueled by progress in precision medicine, wider adoption of digital health platforms, expansion of online pharmacy channels, an increased focus on microbiome research, and rising expenditure on chronic disease management. Among the notable trends shaping the market are microbiome-based therapies, precision medicine, integration of digital therapeutics with mobile health, AI-driven diagnostic tools, remote monitoring technologies, and patient-centered sustainable drug development.

The irritable bowel syndrome (ibs) treatment market size has grown strongly in recent years. It will grow from $7.41 billion in 2025 to $7.97 billion in 2026 at a compound annual growth rate (CAGR) of 7.6%. The growth in the historic period can be attributed to rising prevalence of gastrointestinal disorders, increased diagnosis rates of ibs, growing awareness of digestive health, availability of prescription ibs drugs, expansion of hospital and retail pharmacy networks.

Download a free sample of the irritable bowel syndrome (ibs) treatment market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=11978&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Key Players Dominating the IBS Treatment Industry
Several leading pharmaceutical and biotech companies hold significant positions in the IBS treatment field, including Ironwood Pharmaceuticals Inc., AbbVie Inc., Takeda Pharmaceutical Company Limited, Pfizer Inc., Johnson & Johnson Services Inc., AstraZeneca plc, Novartis AG, Abbott Laboratories, Eli Lilly and Company, and Astellas Pharma Inc. Other notable participants include Bausch Health Companies Inc., Sebela Pharmaceuticals Inc., Prometheus Laboratories Inc., RedHill Biopharma Ltd., Ardelyx Inc., Renexxion Ireland Ltd., 4D Pharma plc, Biora Therapeutics Inc., Salix Pharmaceuticals Ltd., Allergan plc, and Synergy Pharmaceuticals Inc.

Important Corporate Moves Impacting the Market
In a significant move during October 2023, Roche, a Switzerland-based healthcare giant, acquired Telavant Holdings for an undisclosed sum. This acquisition grants Roche the rights to develop, manufacture, and market an innovative IBS treatment in both the United States and Japan. Telavant Holdings is a US biotechnology firm specializing in advanced therapies targeting inflammatory and fibrotic diseases, making this acquisition a strategic addition to Roche's portfolio in gastrointestinal disorders.

View the full irritable bowel syndrome (ibs) treatment market report:
https://www.thebusinessresearchcompany.com/report/irritable-bowel-syndrome-ibs-treatment-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Driving Growth Through Digital Therapeutics and Mobile Applications
A growing number of IBS treatment companies are focusing on digital therapeutics, particularly gut-directed hypnotherapy-based mobile apps designed to boost patient engagement and improve symptom management. These prescription digital platforms provide structured hypnotherapy sessions via smartphones to influence the gut-brain axis. They include features such as guided behavioral therapy, real-time tracking of symptoms, and automated progress monitoring, enhancing treatment accessibility.

For example, in May 2023, Launchit DTx, a Canadian digital health commercialization firm, introduced Regulora-a gut-directed hypnotherapy digital therapeutic aimed at adults managing abdominal pain from IBS. Regulora incorporates evidence-based hypnotherapy modules, clinician-enabled prescribing workflows, and a mobile app for continuous patient response tracking. By offering a non-pharmacologic, digitally delivered option, Regulora supports better self-management and symptom relief for IBS sufferers.

Detailed Segmentation of the IBS Treatment Market
This market is segmented on several bases to better understand its scope and reach:
1) Drug Type:
- Eluxadoline
- Alosetron
- Other Drugs
2) Indication:
- IBS With Constipation
- IBS With Diarrhea
- IBS With Alternating Constipation and Diarrhea
3) Distribution Channel:
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
4) End-Users:
- Hospitals
- Clinics
- Homecare Settings

Subcategories under Drug Type include:
- For Eluxadoline: Treatments for IBS with Diarrhea (IBS-D) and Moderate IBS-D
- For Alosetron: Treatments targeting Severe IBS-D in women and Refractory IBS-D
- For Other Drugs: Medications like Prucalopride, Tenapanor, and Plecanatide

This segmentation reflects the diverse therapeutic options, distribution methods, and patient care settings present in the IBS treatment landscape, supporting tailored approaches to manage this complex disorder effectively.

New analytical features added to our 2026 market reports:

• Market attractiveness scoring and analysis
• Total addressable market (TAM) analysis
• Company scoring matrix graphics and tables
• Excel-based forecasting dashboards
• Market hotspots infographics
• Key technologies and future trend analysis
• Updated graphics and tables

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.